Found: 6
Select item for more details and to access through your institution.
Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Fcγ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder.
- Published in:
- Journal of Immunology Research, 2014, p. 1, doi. 10.1155/2014/264723
- By:
- Publication type:
- Article
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry
- Published in:
- Annals of Hematology, 2021, v. 100, n. 8, p. 2043, doi. 10.1007/s00277-021-04548-2
- By:
- Publication type:
- Article
Burkitt post-transplantation lymphoma in adult solid organ transplant recipients.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 19, p. 4715, doi. 10.1002/cncr.27482
- By:
- Publication type:
- Article
Expert Consensus on the Characteristics of Patients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV<sup>+</sup> PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 3, p. 1267, doi. 10.1007/s12325-022-02383-z
- By:
- Publication type:
- Article
The IPTA Nashville consensus conference on post‐transplant lymphoproliferative disorders after solid organ transplantation in children: IV‐consensus guidelines for the management of post‐transplant lymphoproliferative disorders in children and adolescents
- Published in:
- Pediatric Transplantation, 2024, v. 28, n. 5, p. 1, doi. 10.1111/petr.14781
- By:
- Publication type:
- Article